{"generic":"Abatacept","drugs":["Abatacept","Orencia"],"mono":{"0":{"id":"928482-s-0","title":"Generic Names","mono":"Abatacept"},"1":{"id":"928482-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928482-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Rheumatoid arthritis (Moderate to Severe):<\/b> (IV infusion; less than 60 kg) 500 mg IV infusion over 30 minutes; repeat doses at 2 and 4 weeks after first infusion and every 4 weeks thereafter<\/li><li><b>Rheumatoid arthritis (Moderate to Severe):<\/b> (IV infusion; 60 to 100 kg) 750 mg IV infusion over 30 minutes; repeat doses at 2 and 4 weeks after first infusion and every 4 weeks thereafter<\/li><li><b>Rheumatoid arthritis (Moderate to Severe):<\/b> (IV infusion; more than 100 kg) 1000 mg IV infusion over 30 minutes; repeat doses at 2 and 4 weeks after first infusion and every 4 weeks thereafter<\/li><li><b>Rheumatoid arthritis (Moderate to Severe):<\/b> (SUBQ dosing; with IV loading dose) give weight-based IV loading dose, then 125 mg SUBQ within 1 day of loading dose, followed by 125 mg SUBQ once weekly<\/li><li><b>Rheumatoid arthritis (Moderate to Severe):<\/b> (SUBQ dosing; without IV loading dose) 125 mg SUBQ weekly<\/li><li><b>Rheumatoid arthritis (Moderate to Severe):<\/b> (transitioning from IV to SUBQ therapy) 125 mg SUBQ in place of next scheduled IV dose, followed by 125 mg SUBQ once weekly<\/li><\/ul>"},"1":{"id":"928482-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Juvenile idiopathic arthritis (Moderate to Severe), active, polyarticular:<\/b> (6 yr or older; weighing less than 75 kg) 10 mg\/kg given by IV infusion over 30 min; repeat doses at 2 and 4 weeks after first infusion and every 4 weeks thereafter<\/li><li><b>Juvenile idiopathic arthritis (Moderate to Severe), active, polyarticular:<\/b> (6 yr or older; weighing 75 kg to 100 kg) 750 mg given by IV infusion over 30 min; repeat doses at 2 and 4 weeks after first infusion and every 4 weeks thereafter<\/li><li><b>Juvenile idiopathic arthritis (Moderate to Severe), active, polyarticular:<\/b> (6 yr or older; weighing more than 100 kg) 1000 mg given by IV infusion over 30 min; repeat doses at 2 and 4 weeks after first infusion and every 4 weeks thereafter<\/li><\/ul>"},"3":{"id":"928482-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Juvenile idiopathic arthritis (Moderate to Severe), active, polyarticular<\/li><li>Rheumatoid arthritis (Moderate to Severe)<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Rheumatoid arthritis, Early Disease, Methotrexate Naive with Poor Prognostic Factors<br\/>"}}},"3":{"id":"928482-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928482-s-3-9","title":"Contraindications","mono":"Specific contraindications have not been determined <br\/>"},{"id":"928482-s-3-10","title":"Precautions","mono":"<ul><li>Hepatic:<\/li><li>-- Hepatitis B reactivation has been associated with antirheumatic therapies; screen for viral hepatitis prior to initiating therapy<\/li><li>Immunologic:<\/li><li>-- Hypersensitivity reactions, including anaphylaxis or anaphylactoid reactions, have been reported; permanent discontinuation recommended<\/li><li>--Serious infections (eg, sepsis, pneumonia), including fatalities, have been reported, especially with concomitant immunosuppressant therapy; caution advised in patients with a history of recurrent infections, underlying conditions which predispose to infections, or chronic, latent, or localized infections; discontinue if a serious infection develops<\/li><li>Respiratory:<\/li><li>-- Screen for latent TB prior to initiating therapy and treat if positive<\/li><li>-- COPD; increased risk for adverse effects and disease exacerbation; monitoring recommended<\/li><li>Concomitant Use:<\/li><li>-- Concurrent use of tumor necrosis factor antagonists is not recommended<\/li><li>-- Do not give live vaccines during or within 3 months after abatacept therapy<\/li><li>-- Concurrent use of other biologic rheumatoid arthritis therapy, including anakinra, is not recommended<\/li><\/ul>"},{"id":"928482-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"928482-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"928482-s-4","title":"Drug Interactions","sub":{"1":{"id":"928482-s-4-14","title":"Major","mono":"<ul><li>Adalimumab (theoretical)<\/li><li>Anakinra (theoretical)<\/li><li>Etanercept (established)<\/li><li>Golimumab (theoretical)<\/li><li>Infliximab (theoretical)<\/li><\/ul>"},"2":{"id":"928482-s-4-15","title":"Moderate","mono":"<ul><li>Adenovirus Vaccine Type 4, Live (probable)<\/li><li>Adenovirus Vaccine Type 7, Live (probable)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (probable)<\/li><li>Influenza Virus Vaccine, Live (probable)<\/li><li>Measles Virus Vaccine, Live (probable)<\/li><li>Mumps Virus Vaccine, Live (probable)<\/li><li>Poliovirus Vaccine, Live (probable)<\/li><li>Rotavirus Vaccine, Live (probable)<\/li><li>Rubella Virus Vaccine, Live (probable)<\/li><li>Smallpox Vaccine (probable)<\/li><li>Typhoid Vaccine (probable)<\/li><li>Varicella Virus Vaccine (probable)<\/li><li>Yellow Fever Vaccine (probable)<\/li><\/ul>"}}},"5":{"id":"928482-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Nausea (5% or greater)<\/li><li><b>Immunologic:<\/b>Infectious disease (37.6% to 54%)<\/li><li><b>Neurologic:<\/b>Headache (Adult, 12.4% to 18%; pediatric, 5% or greater)<\/li><li><b>Respiratory:<\/b>Nasopharyngitis (12% to 18%), Upper respiratory infection (10% or greater)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Cellulitis (0.2% to 0.5%)<\/li><li><b>Gastrointestinal:<\/b>Diverticulitis (0.2% to 0.5%)<\/li><li><b>Immunologic:<\/b>Anaphylaxis (Less than 0.1%), Infectious disease, Serious (3%), Sepsis<\/li><li><b>Renal:<\/b>Pyelonephritis, acute (0.2% to 0.5%), Urinary tract infectious disease (6%)<\/li><li><b>Respiratory:<\/b>Acute exacerbation of chronic obstructive pulmonary disease (8%), Bronchitis (5% to 13%), Pneumonia (Less than 5%)<\/li><li><b>Other:<\/b>Cancer (1.3%)<\/li><\/ul>"},"6":{"id":"928482-s-6","title":"Drug Name Info","sub":{"0":{"id":"928482-s-6-17","title":"US Trade Names","mono":"Orencia<br\/>"},"2":{"id":"928482-s-6-19","title":"Class","mono":"<ul><li>Antirheumatic<\/li><li>Immune Modulator<\/li><\/ul>"},"3":{"id":"928482-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928482-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928482-s-7","title":"Mechanism Of Action","mono":"Abatacept is a cytotoxic T lymphocyte antigen immunoglobulin (CTLA-4 Ig), a fusion protein, which consists of CTLA linked to modified heavy-chain constant region of human IgG1. It is a biological response modifier that demonstrates anti-inflammatory effects by downregulating T cell activation. Abatacept binds to CD80 and CD86 receptors on the antigen-presenting cell and prevents them from binding to CD28 on the T cell for optimal T cell activation.<br\/>"},"8":{"id":"928482-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"928482-s-8-23","title":"Absorption","mono":"Bioavailability, subQ: 78.6% <br\/>"},"1":{"id":"928482-s-8-24","title":"Distribution","mono":"<ul><li>Vd, IV: 0.07 L\/kg<\/li><li>Vd, subQ: 0.11 L\/kg<\/li><\/ul>"},"3":{"id":"928482-s-8-26","title":"Excretion","mono":"<ul><li>Total body clearance, IV, adults: 0.22 mL\/hr\/kg<\/li><li>Total body clearance, IV, pediatric: 0.4 mL\/hr\/kg<\/li><li>Total body clearance, subQ: 0.28 mL\/hr\/kg<\/li><\/ul>"},"4":{"id":"928482-s-8-27","title":"Elimination Half Life","mono":"<ul><li>IV: 13 days<\/li><li>subQ: 14.3 days<\/li><\/ul>"}}},"9":{"id":"928482-s-9","title":"Administration","mono":"<ul><li><b>Intravenous<\/b><br\/><ul><li>use ONLY the silicone-free disposable syringe provided with each vial; discard any solutions inadvertently reconstituted with a siliconized syringe<\/li><li>additional silicone-free disposable syringes may be obtained by contacting Bristol-Myers Squibb at 1-800-ORENCIA<\/li><li>during reconstitution to dissolve powder with 10 mL of sterile water for injection, rotate gently and DO NOT shake vial (to avoid foaming)<\/li><li>after reconstitution, vent the vial with a needle to dissipate any foam that may be present<\/li><li>concentration of the reconstituted solution is 25 mg\/mL<\/li><li>further dilution to 100 mL is necessary; from a 100 mL NS infusion bag or bottle, withdraw a volume equal to the volume of reconstituted solution required for the patient's dose; slowly add the reconstituted abatacept solution from each vial into the infusion bag or bottle using the same silicone-free disposable syringe provided with each vial; gently mix<\/li><li>final concentration will depend on the amount of drug added; discard remaining solution in vials<\/li><li>administer over 30 minutes with an infusion set and a sterile, nonpyrogenic, low-protein-binding filter (pore size of 0.2 micrometer to 1.2 micrometer)<\/li><li>complete infusion within 24 hours of reconstitution; diluted infusion solution may be stored at room temperature or refrigerated at 2 degrees C to 8 degrees C (36 degrees F to 46 degrees F) before use<\/li><li>should not be infused concomitantly in the same intravenous line with other agents<\/li><\/ul><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>single-dose prefilled syringe is only for subQ administration; not for IV infusion<\/li><li>rotate injection sites; do not give in areas where skin is tender, bruised, red, or hard<\/li><\/ul><\/li><\/ul>"},"10":{"id":"928482-s-10","title":"Monitoring","mono":"<ul><li>C-reactive protein; erythrocyte sedimentation rate (ESR); rheumatoid factor<\/li><li>infections (chronic, latent, or localized); patients who develop a new infection during treatment should be monitored closely<\/li><li>respiratory status should be monitored in patients with chronic obstructive pulmonary disease<\/li><li>signs and symptoms of anaphylaxis, anaphylactoid reaction, and hypersensitivity reactions (hypotension, urticaria, and dyspnea)<\/li><li>signs and symptoms of malignancy (drugs that inhibit T cell activation including abatacept affect the host defenses against malignancies)<\/li><li>symptom improvement (e.g., tender\/swollen joints, morning stiffness, pain)<\/li><li>tuberculin skin test prior to initiating abatacept.<\/li><\/ul>"},"11":{"id":"928482-s-11","title":"How Supplied","mono":"<b>Orencia<\/b><br\/><ul><li>Intravenous Powder for Solution: 250 MG<\/li><li>Subcutaneous Solution: 125 MG\/ML<\/li><\/ul>"},"13":{"id":"928482-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient that live vaccines should be avoided during and for 3 months after therapy.<\/li><li>Counsel diabetic patient using a GDH-PQQ based glucose test that alternative testing is needed on days they receive IV abatacept due to the maltose in the solution.<\/li><li>Drug may cause fever, nausea, diarrhea, abdominal pain, headaches, nasopharyngitis, cough, or upper respiratory infections.<\/li><li>Instruct patient about increased risk of infection and to report signs\/symptoms of a new infection or a recurring infection (hepatitis B, tuberculosis) during therapy.<\/li><li>Warn COPD patient that drug may exacerbate respiratory symptoms.<\/li><li>Advise patient about proper injection sites and rotation.<\/li><\/ul>"}}}